Mesenchymal Stem Cell Therapy for Parkinson's Disease

📖 Wiki Page

therapeutic1605 wordssynced 2026-04-02

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

flowchart TD Mesenchymal_Stem_Cell_Therapy_["Mesenchymal Stem Cell Therapy for Parkinsons Dis"] Mesenchymal_Stem_Cell_Therapy_["Parkinson"] Mesenchymal_Stem_Cell_Therapy_ -->|"related to"| Mesenchymal_Stem_Cell_Therapy_ style Mesenchymal_Stem_Cell_Therapy_ fill:#81c784,stroke:#333,color:#000 Mesenchymal_Stem_Cell_Therapy_["table"] Mesenchymal_Stem_Cell_Therapy_ -->|"related to"| Mesenchymal_Stem_Cell_Therapy_ style Mesenchymal_Stem_Cell_Therapy_ fill:#81c784,stroke:#333,color:#000 Mesenchymal_Stem_Cell_Therapy_["class"] Mesenchymal_Stem_Cell_Therapy_ -->|"related to"| Mesenchymal_Stem_Cell_Therapy_ style Mesenchymal_Stem_Cell_Therapy_ fill:#81c784,stroke:#333,color:#000 style Mesenchymal_Stem_Cell_Therapy_ fill:#4fc3f7,stroke:#333,color:#000

...

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Mesenchymal Stem Cell Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Treatment Name</td>
<td>Mesenchymal Stem Cell (MSC) Therapy for PD</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mesenchymal Stromal Cells</td>
</tr>
<tr>
<td class="label">Target Indication</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Neurotrophic secretion, immunomodulation, mitochondrial transfer</td>
</tr>
<tr>
<td class="label">Delivery Routes</td>
<td>Intravenous, intrathecal, stereotactic</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1/2 trials</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Function in PD</td>
</tr>
<tr>
<td class="label">GDNF</td>
<td>Potent neurotrophin for dopaminergic neurons; promotes survival and process outgrowth</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Supports neuronal plasticity, synaptic function, and dopamine signaling</td>
</tr>
<tr>
<td class="label">VEGF</td>
<td>Promotes neurovascular unit health, improves blood-brain barrier function</td>
</tr>
<tr>
<td class="label">IGF-1</td>
<td>Supports neuronal metabolism and survival</td>
</tr>
<tr>
<td class="label">HGF</td>
<td>Anti-inflammatory and neuroprotective properties</td>
</tr>
<tr>
<td class="label">Source</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Bone Marrow (Autologous)</td>
<td>Well-characterized, no immune issues</td>
</tr>
<tr>
<td class="label">Bone Marrow (Allogeneic)</td>
<td>Younger cells, standardized</td>
</tr>
<tr>
<td class="label">Umbilical Cord (Wharton's Jelly)</td>
<td>Higher proliferative capacity, immunomodulatory</td>
</tr>
<tr>
<td class="label">Adipose Tissue</td>
<td>Abundant source, easy collection</td>
</tr>
<tr>
<td class="label">Dental Pulp</td>
<td>Neural crest origin, easy access</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">NCT00911326</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">NCT01827180</td>
<td>University of Poona</td>
</tr>
<tr>
<td class="label">NCT02611167</td>
<td>Saudi German Hospital</td>
</tr>
<tr>
<td class="label">NCT04521368</td>
<td>Shanghai Sixth People's Hospital</td>
</tr>
<tr>
<td class="label">NCT04881461</td>
<td>HEALIOS K.K. (Japan)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Minimally invasive, systemic effect</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF delivery, reaches brain surfaces</td>
</tr>
<tr>
<td class="label">Stereotactic</td>
<td>Precise brain targeting, high local concentration</td>
</tr>
<tr>
<td class="label">Intra-arterial</td>
<td>High CNS exposure</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>MSC Therapy</td>
</tr>
<tr>
<td class="label">Primary Mechanism</td>
<td>Neuroprotection, trophic support</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>IV/Intrathecal</td>
</tr>
<tr>
<td class="label">Invasiveness</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Repeat Dosing</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Dopamine Restoration</td>
<td>Indirect via trophic support</td>
</tr>
<tr>
<td class="label">Risk of Tumor</td>
<td>Very low</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Relatively simple</td>
</tr>
<tr>
<td class="label">Timeline to Access</td>
<td>Earlier</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Product</td>
</tr>
<tr>
<td class="label">BrainStorm Cell Therapeutics</td>
<td>MSC-NTF (NurOwn platform)</td>
</tr>
<tr>
<td class="label">HEALIOS K.K.</td>
<td>Allogeneic MSCs</td>
</tr>
<tr>
<td class="label">Cynata Therapeutics</td>
<td>CYP-001</td>
</tr>
</table>

Mesenchymal Stem Cell (MSC) Therapy for Parkinson's Disease represents a distinct therapeutic approach from the dopaminergic neuron replacement strategies (iPSC/ESC-derived neurons). While cell replacement aims to substitute lost [dopaminergic neurons](/cell-types/vulnerable-dopaminergic-pd), MSC therapy focuses on neuroprotection, immunomodulation, and trophic support to preserve remaining neurons and slow disease progression.

Rationale for MSC Therapy in PD

Why Neuroprotection Over Replacement?

Several factors make MSC-based neuroprotection an attractive complementary approach:

Preserve Existing Circuitry: Rather than rebuilding neural circuits (which requires precise integration), MSC therapy protects the [substantia nigra pars compacta](/brain-regions/substantia-nigra) neurons that remain

Multi-Target Mechanism: Addresses multiple pathogenic pathways simultaneously (inflammation, oxidative stress, mitochondrial dysfunction)

Accessibility: MSCs can be delivered via less invasive routes than stereotactic neuron transplantation

Repeat Dosing: Multiple administrations possible as disease progresses

Combination Potential: Can be combined with other disease-modifying approaches

Disease Context

[Parkinson's disease](/diseases/parkinsons-disease) involves:

Progressive loss of [dopaminergic neurons](/cell-types/substantia-nigra-dopamine-parkinsons) in the [substantia nigra](/brain-regions/substantia-nigra)
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation into [Lewy bodies](/entities/lewy-bodies)
Chronic [neuroinflammation](/mechanisms/neuroinflammation) with activated [microglia](/cell-types/microglia)
Mitochondrial dysfunction and oxidative stress
Neurotrophic factor deficiency

MSC therapy directly addresses several of these mechanisms.

Mechanism of Action

Immunomodulation

MSCs exert powerful immunomodulatory effects critical for PD:

Microglial Modulation

Shift [microglia](/cell-types/microglia) from pro-inflammatory M1 to protective M2 phenotype
Reduce production of pro-inflammatory cytokines (IL-1β, TNF-α, IFN-γ)
Increase anti-inflammatory cytokines (IL-10, TGF-β)

T-Cell Regulation

Suppress pro-inflammatory T-cell responses
Promote regulatory T-cell (Treg) populations
Reduce autoimmunity that may contribute to neurodegeneration

Neurotrophic Factor Secretion

MSCs secrete multiple neurotrophic factors that support [dopaminergic neuron](/cell-types/vulnerable-dopaminergic-pd) survival:

Mitochondrial Transfer

A unique mechanism by which MSCs transfer functional mitochondria to damaged neurons:

Tunneling Nanotubes: Form direct cytoplasmic connections with stressed neurons
Metabolic Rescue: Restore ATP levels in neurons with impaired energy metabolism
Bioenergetic Support: Improve neuronal viability under oxidative stress conditions
Particularly Relevant in PD: Mitochondrial dysfunction is a core feature of [Parkinson's disease pathogenesis](/mechanisms/mitochondrial-dysfunction-parkinson)

Anti-Apoptotic Effects

Secreted factors activate pro-survival signaling cascades (PI3K/Akt, MAPK/ERK)
Reduce caspase activation and programmed cell death
Protect neurons from excitotoxicity
Preserve synaptic connections

Alpha-Synuclein Modulation

Emerging evidence suggests MSCs may influence [alpha-synuclein](/proteins/alpha-synuclein) pathology:

Exosome-mediated clearance mechanisms
Reduction of [alpha-synuclein aggregation](/mechanisms/alpha-synuclein-aggregation-pathway)
Protection against prion-like spread

MSC Sources for PD Therapy

Clinical Trials in Parkinson's Disease

Completed and Active Trials

Key Clinical Findings

Phase 1/2 Trials (2014-2016)

MSC transplantation was safe and well-tolerated
Some patients showed improved motor scores (UPDRS Part III)
No significant adverse events related to cell administration
Reference: PMID:24721108, PMID:28182767

Mechanism Evidence

Elevated neurotrophic factors in CSF of treated patients
PET imaging showed reduced neurodegeneration in some patients
Immunomodulatory effects confirmed in biomarker studies

Ongoing Programs

HEALIOS K.K. (Japan)

Allogeneic MSC product
Phase 1/2 trial for PD
Focus on safety and preliminary efficacy

International Consortium Trials

Multi-center trials combining different MSC sources
Focus on optimizing delivery routes and cell dosing

Delivery Routes Comparison

Optimal Route Selection

For PD, intrathecal or intravenous delivery is most commonly used:

Allows repeated administrations
Targets neuroinflammation systemically
Less invasive than neurosurgery

Stereotactic delivery targets [substantia nigra](/brain-regions/substantia-nigra) directly but is more invasive.

Comparison: MSC vs. Dopaminergic Neuron Replacement

Complementary Approaches

These approaches are not mutually exclusive:

Early Disease: MSC therapy to protect neurons and slow progression
Later Disease: Neuron replacement when significant cell loss has occurred
Combination: MSC therapy alongside neuron replacement for synergistic effects

Companies and Programs

Clinical-Stage Programs

Research Programs

Multiple universities in Korea, Japan, China, and Europe have active MSC-PD programs
International Stem Cell Corporation (ISCO) exploring MSC derivatives for PD

Therapeutic Potential and Challenges

Potential Benefits

Disease Modification: Targets multiple pathogenic pathways simultaneously

Neuroprotection: Preserves remaining dopaminergic neurons

Symptomatic Relief: May improve motor function through trophic support

Autologous Option: Patient's own cells reduce rejection risk

Repeat Administrations: Can be re-treated as disease progresses

Accessible: Less invasive than surgical cell transplantation

Challenges

Limited CNS Delivery: Blood-brain barrier limits intravenous delivery

Variable Potency: MSC preparations vary between donors and sources

Survival in CNS: Unclear how long administered MSCs persist

Optimal Dose: Not established for PD

Durability: Unknown duration of benefit

Regulatory Pathway: Cell therapy regulatory challenges

Patient Selection Considerations

MSC therapy may be most appropriate for:

Early-to-mid stage PD (Hoehn & Yahr 1-3)
Patients with significant neuroinflammation markers
Those seeking disease-modifying approaches
Patients with contraindications to surgical interventions

Combination Therapies

Synergistic Approaches

MSC therapy may be enhanced when combined with:

GDNF/BDNF Direct Delivery: Combined trophic support

Small Molecules: MAO-B inhibitors, dopamine agonists

Immunomodulatory Drugs: Anti-inflammatory agents

Physical Therapy: Rehabilitation to enhance functional outcomes

Gene Therapy: AAV-based neurotrophic factor expression

Research Pipeline

MSC plus neurotrophic factor combination trials in planning
Gene-modified MSCs (enhanced GDNF secretion) in preclinical development
MSC-derived exosomes as cell-free alternative

Safety Profile

Observed Safety in PD Trials

Generally well-tolerated across trials
Common adverse events: Headache, injection site pain
No significant immune reactions with autologous cells
No tumor formation observed in long-term follow-up
Low rates of serious adverse events

Long-Term Monitoring

Continued monitoring for potential delayed effects
Assessment of durability of benefit
Impact on disease progression over years

Future Directions

Next-Generation Approaches

Gene-Enhanced MSCs: Engineering MSCs to produce higher GDNF/BDNF levels

Exosome Therapy: Cell-free alternative using MSC-derived exosomes

Biomaterial Scaffolds: Supporting MSC survival and distribution

Combination Approaches: MSC therapy with other disease-modifying agents

Clinical Development Needs

Larger, controlled trials with standardized endpoints
Biomarker development to predict response
Optimal patient selection criteria
Long-term follow-up studies
Comparison of delivery routes

References

[Ventimiglia et al., Mesenchymal Stem Cells for Parkinson's Disease Neurodegeneration. Cells (2022)](https://doi.org/10.3390/cells11071158)

[Daniele et al., Therapeutic potential of MSC in Parkinson's disease. J Transl Med (2021)](https://pubmed.ncbi.nlm.nih.gov/34266456/)

[Park et al., MSC exosomes ameliorate alpha-synuclein aggregation. Mol Brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34238314/)

[Schiess et al., Phase 1/2a trial of autologous MSC therapy for Parkinson's disease. Nat Med (2022)](https://doi.org/10.1038/s41591-022-01789-0)

[Intrastriatal transplantation of autologous mesenchymal stem cells. Eur J Neurol (2007)](https://pubmed.ncbi.nlm.nih.gov/17666013/)

📖 View canonical wiki page →

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

Rationale for MSC Therapy in PD

Why Neuroprotection Over Replacement?

Disease Context

Mechanism of Action

Immunomodulation

Neurotrophic Factor Secretion

Mitochondrial Transfer

Anti-Apoptotic Effects

Alpha-Synuclein Modulation

MSC Sources for PD Therapy

Clinical Trials in Parkinson's Disease

Completed and Active Trials

Key Clinical Findings

Ongoing Programs

Delivery Routes Comparison

Optimal Route Selection

Comparison: MSC vs. Dopaminergic Neuron Replacement

Complementary Approaches

Companies and Programs

Clinical-Stage Programs

Research Programs

Therapeutic Potential and Challenges

Potential Benefits

Challenges

Patient Selection Considerations

Combination Therapies

Synergistic Approaches

Research Pipeline

Safety Profile

Observed Safety in PD Trials

Long-Term Monitoring

Future Directions

Next-Generation Approaches

Clinical Development Needs

See Also

References